Skip to Content

Rigel Pharmaceuticals Inc RIGL Stock Quote

| Rating as of


Morningstar‘s Stock Analysis RIGL

There is no Morningstar’s Analysis data available.

Key Statistics RIGL

Company Profile RIGL

Business Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

1180 Veterans Boulevard
South San Francisco, CA, 94080
T +1 650 624-1100
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 165